Physician profile
Michael P Ondich
NPI 1871587394
$3,200.63
in general payments reported to CMS, 2019-2025
18 companies · $350 in 2025
The $350 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $493 · 2020: $74.69 · 2021: $544 · 2022: $821 · 2023: $474 · 2024: $445 · 2025: $350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,268.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $987.23 | 2019-2025 | Wegovy, Saxenda |
| Glaxosmithkline, LLC. | $640.60 | 2021-2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $347.52 | 2019-2025 | Jardiance, Tradjenta |
| Lilly USA, LLC | $233.58 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $224.92 | 2019-2023 | Steglatro, Verquvo, Steglujan |
| Pfizer INC. | $202.18 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $199.65 | 2019-2022 | |
| Amarin Pharma, INC. | $68.39 | 2021-2022 | |
| Exact Sciences Corporation | $45.11 | 2025 | Cologuard Collection Kit |
| Allergan, INC. | $43.60 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.63 | 2022 | |
| Esperion Therapeutics, INC. | $34.30 | 2025 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $34.28 | 2024 | |
| Amgen INC. | $31.38 | 2019 | |
| Novartis Pharmaceuticals Corporation | $22.35 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $18.73 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Astellas Pharma US INC | $13.83 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ondich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.